Prestige Consumer Healthcare Inc.

What Do They Do?

Develops, markets and sells branded over-the-counter health and personal care products to retailers and e-commerce channels in North America and other international markets.

How Do They Make Money?

Retailers and e-commerce channels pay for finished consumer health products when goods ship to a carrier or are picked up; payment follows within one year or less.

revenue

Segment	Share	How money arrives
Analgesics Sold outright	10% FY2023: 11%	Sold outright
Cough & Cold Sold outright	9.4% FY2023: 11%	Sold outright
Women's Health Sold outright	21% FY2023: 22%	Sold outright
Gastrointestinal Sold outright	24% FY2023: 20%	Sold outright
Eye & Ear Care Sold outright	13% FY2023: 15%	Sold outright
Dermatologicals Sold outright	12% FY2023: 11%	Sold outright
Oral Care Sold outright	9.3% FY2023: 8.7%	Sold outright
Other OTC Sold outright	1.4% FY2023: 1.0%	Sold outright

Who Are Their Customers?

Sells to retailers and e-commerce channels, including mass merchandisers, drug wholesalers, food, dollar, convenience and club stores. Its sales team and third-party sales firms work directly with customers.

Customers above 10% of revenue, FY2026

of revenue from two customers (20%, 15%)

FY2024: 31% from two customers

Do Revenues Turn Into Profits?

Yes. It kept 17 cents of every revenue dollar as net income in FY2026 and turned 23 cents into free cash flow.

Operating income, FY2026

28% of revenue

▼ −8% vs FY2025 ($336.8M, 30%)

Net income, FY2026

17% of revenue

▼ −11% vs FY2025 ($214.6M, 19%)

Free cash flow, FY2026

23% of revenue

▲ +1% vs FY2025 ($243.3M, 21%)

How Are They Changing?

Since the FY2026 annual report

Latest quarter: Q1 FY2027, the three months to Jun 30, 2026

Revenue: ▲ +6%; vs $249.5M in Q1 FY2026
Net income: ▼ −39%; vs $47.5M in Q1 FY2026

Gastrointestinal share of revenue vs 23.2% in Q1 FY2026

Aug 6, 2026 Raised fiscal 2027 revenue and earnings outlook The increase accounts for the Breathe Right and LaCorium acquisitions.
Jul 6, 2026 Completed the LaCorium Health Australia acquisition
Jun 16, 2026 Completed acquisition of Breathe Right and other brands

Flat. Revenue was $1.1B in FY2026, about the same as the $1.1B of FY2022.

Revenue over time

Analgesics Cough & Cold Women's Health Gastrointestinal Eye & Ear Care Dermatologicals Oral Care Other OTC

$2B$1B$0

FY2022 FY2023 FY2024 FY2025 FY2026